<DOC>
	<DOCNO>NCT01712347</DOCNO>
	<brief_summary>This multicenter observational study evaluate efficacy safety first-line bevacizumab ( Avastin ) combination fluoropyrimidine-based chemotherapy participant metastatic colorectal cancer ( mCRC ) . Participants treat physician decide initiate first-line fluoropyrimidine base chemotherapy combination bevacizumab observe approximately 4 year .</brief_summary>
	<brief_title>An Observational Study First-Line Bevacizumab ( Avastin ) With Fluoropyrimidine-Based Chemotherapy Participants With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Participants histologically confirm metastatic colorectal cancer receive bevacizumab combination firstline fluoropyrimidinebased chemotherapy Participants qualify bevacizumab treatment accord local label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>